Key facts: 2027 FDA bid, Phase 3 trials; analysts cut targets

Celldex Therapeutics plans FDA approval for barzolvolimab in 2027 and is conducting Phase 3 trials. Barclays cut its price target to $50, while HC Wainwright reduced theirs to $58, both maintaining positive ratings. The stock closed at $27.96 on Nov. 19.

Original reporting
Published Nov 21, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 8:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Key facts: 2027 FDA bid, Phase 3 trials; analysts cut targets — source image
Decision brief

The 30-second read

$CLDXBearishMed
01

Why it matters

Analyst target reductions reflect weaker near‑term expectations, while the FDA timeline adds long‑term uncertainty, likely pressuring the stock.

02

Market read

The combined analyst downgrades and distant FDA filing create short‑term downside risk for CLDX, with limited broader market impact.

03

What to watch

Potential partnership or licensing deals for barzolvolimab could mitigate downside if announced.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Celldex (CLDX) announced plans for a 2027 FDA submission for barzolvolimab and ongoing Phase 3 trials, while Barclays and HC Wainwright cut price targets.

Company-level read

Ticker impact

$CLDXBearishHigh confidence
Context

Barzolvolimab FDA bid for 2027 and analyst target cuts to $50/$58 provide fresh corporate and regulatory news for Celldex.

Expected impact

likely pressure as the market prices in lower price targets and the long‑term FDA timeline adds uncertainty

Evidence & confidence

Target reductions from $53 to $50 and $64 to $58 signal weaker expectations; the 2027 FDA filing does not offset short‑term sentiment.

Market effects

Biotech sector may see modest caution on late‑stage trial timelines.

U.S. biotech investors likely to reassess near‑term valuations.

Limited; primarily affects U.S. listed biotech exposure.

Counterpoint

Long‑term investors might view the 2027 FDA filing as a catalyst for future upside despite short‑term target cuts.

Key entities

  • Celldex

    Biotech firm developing barzolvolimab.

  • Barclays

    Maintains Overweight rating, cuts target to $50.

  • HC Wainwright

    Retains Buy rating, lowers target to $58.

Related articles

$CLDXMed

Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff

Celldex Therapeutics will halt development of barzolvolimab for eczema after Phase 2 trial failure, but plans approval filing for chronic hives. NChroma Bio will cut staff and explore strategic alternatives after halting hepatitis B drug testing. Isomorphic Labs partners with Merck for cancer drug development. Teva Pharmaceuticals' R&D chief is leaving, but analysts remain confident. VitriVax raised $87M for Lyme disease vaccine development.

$CLDXMed

Celldex discontinues atopic dermatitis program after trial miss

Celldex Therapeutics (CLDX) halted development of barzolvolimab for atopic dermatitis after a Phase 2 trial missed primary and key secondary endpoints. The study, involving 131 patients, showed no significant improvement over placebo. The company plans to pursue other indications, including chronic spontaneous urticaria, with a BLA submission expected in 2027. Barzolvolimab demonstrated a favorable safety profile.

$CLDXMed

Celldex Reports Third Quarter Financial Results and Provides Corporate Update

Celldex Therapeutics, Inc. (CLDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Celldex Reports Third Quarter Financial Results and Provides Corporate Update Best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab’s potential to be a transformational therapy in